Project description
A fast and effective handheld device for early cancer diagnostics
Nucleic acid amplification tests are used to detect small amounts of nucleic acids, or genetic materials such as cancerous cells, viruses or bacteria associated with illness. They are still largely performed in centralised laboratories by highly trained personnel using expensive instrumentation. The Polish SME Genomtec has developed patented nucleic acid amplification technology as well as a point-of-care device (Genomtec Tumor) for rapid cancer diagnosis within 20 minutes. It can be operated with minimal to no training, thanks to a lab-on-chip analysis system and the extraction of genetic material directly onto a reaction card that's inserted into the device. The procedure is completely automated and costs a fraction of what real-time polymerase chain reaction amplification does. EU funding of the GenomtecTumor project is helping the team prepare for commercialisation.
Objective
The goal of this project is to develop a portable and easy to use device for early cancer diagnosis to maximise patient outcomes.
Cancer is a major public health problem and a leading cause of morbidity and death with over 14.1 million cases reported worldwide
every year. Early cancer diagnosis is critical to its successful treatment, yet today’s technologies are limited in their accuracy, and are
laborious and time consuming processes.
Genomtec aims to address this challenge with its novel diagnostic system based on unique, patent pending amplification
technology – Streamlined Nucleic Acid Amplification Technology (SNAATTM). Genomtec’s programme is built on many years of R&D
activity and collaborative projects with academic and medical institutions in Poland. Using this robust molecular biology method for
real-time amplification of nucleic acids, Genomtec’s cancer diagnostic test can be performed in 20 minutes at the point-of-care.
Genomtec offers the possibility to accurately diagnose cancer early and reduce its financial burden on the economy by enabling
more effective treatment and improved patient outcomes, including increased patient survival, increased post-treatment quality of
life, and reduced patient distress during the diagnostic phase. Genomtec’s diagnostic device is unique and there are no competitors
using the same molecular approach to diagnose cancer based on detection of tumour specific microRNA.
The ultimate success of this project will depend on the generation of clinical data which will improve opportunities for sales
expansion. Genomtec plans to apply for the SME Phase 2 grant to take its product through device finalisation, clinical studies, and
establishment of the distribution network. Genomtec has an established business development contact network and has been
awarded numerous prizes for its innovativeness and potential for growth, e.g. The best non-US startup at Boston HUBWeek in
October 2018.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences public health
- natural sciences biological sciences biochemistry biomolecules nucleic acids
- medical and health sciences clinical medicine oncology
- natural sciences biological sciences molecular biology
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
50 428 WROCLAW
Poland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.